←
Narendranath Epperla, MD, MS, FACP180 posts
Narendranath Epperla, MD, MS, FACP avatar

Narendranath Epperla, MD, MS, FACP

@NEpperla

Lymphoma specialist at HCI

◷ Joined July 2017▧ 1 Photos and videos
Blood Journals Portfolio avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Blood Journals Portfolio@BloodPortfolio·Jun 19

Axi-cel and tisa-cel both demonstrated efficacy in patients with R/R FL in real-world settings, although PFS was inferior to that observed in clinical trials. Read the full article in Blood Advances: ow.ly/rNFG50Zepwm

Post attachment
Ajay Major, MD, MBA avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Ajay Major, MD, MBA@majorajay·May 6

NAVD real-world outcomes #lymsm - 327 pts, med age 37, 24% ≥60 yrs - ORR 94% (CR 86%) - 1-yr PFS 94.5%, OS 99.7% - irAEs in 29% (9% G3+) - febrile neutropenia 10%, infections 25% (10% G3+) RW efficacy mirrors S1826, though notably ⬆️ infections (despite GCSF) & irAEs. pmc.ncbi.nlm.nih.gov/article…

Post attachment
Lymphoma Hub avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Lymphoma Hub@lymphomahub·9 Oct 2025

CONGRESS | #IACH | PRESENTATION Naren Epperla @NEpperla @huntsmancancer provides an overview of innovations in the prognostic assessment of patients with lymphoma. They discuss the prognostic utility of ctDNA by PhaseED-Seq at EOT in patients with 1L DLBCL, the relevance of interim PET after C4 in FL, and the use of prognostic models in EMZL. Follow our live feed for more updates: loom.ly/VEha6BE Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress

Post attachmentPost attachmentPost attachmentPost attachment
Kepecs Lab avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Kepecs Lab@KepecsLab·10 Apr 2025

1/ Why do late-stage cancer patients lose motivation & sink into apathy? 🔥Our new Science paper shows cancer activates a cytokine-sensing brain circuit to lower motivation.Great work by Aelita Zhu @sarahstarosta @Pignatelli_Lab @JanowitzTobias &team!🧵 🔗 doi.org/10.1126/science.adm8…

Muzaffar Qazilbash avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Muzaffar Qazilbash@Transplant_Doc·20 Mar 2025

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm @DrMarcosdelima @NEpperla jhoonline.biomedcentral.com/…

UofU3i avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
UofU3i@UofU3i·7 Jan 2025

New 3i Investigator Article Alert!! Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma pubmed.ncbi.nlm.nih.gov/3975…

Daniel Addison, MD avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Daniel Addison, MD@md_addison·19 Oct 2024

Cardiac considerations with Emerging Cancer Cellular Therapies: ashpublications.org/bloodadv… Thanks @BloodAdvances for publishing this work. Excellent work by @MalakMunirMD @ASayedMD @NEpperla #cardioonc #cancer #leukemia #lymphoma

Post attachmentPost attachment

Cardiotoxicity is a significant concern with novel T-cell therapies 🫀🎯 Our recent review in @BloodAdvances explores: -Reported rates 📊 -Risk factors ⚠️ -Management strategies 🩺 -Unanswered questions 🔍 Full paper 👉 10.1182/bloodadvances.2024013849 #CardioOnc #MedTwitter

Andrew M. Evens, DO, MBA, MSc avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Andrew M. Evens, DO, MBA, MSc@DrAEvens·11 Dec 2023

We are looking forward to working on this more- adding ⬆️ cases & analyses (45-49% vs <45% split was arbitrary but may be relevant). Much more work in this area is needed as these #lymphoma pts are often excluded from clinical trials. @NEpperla @DrRaulCordoba #ASH23 #CardioOnc

Annunzio et al: cHL & cardiomyopathy - 16 US ctrs, pts with EF < 50% - split 45-49% & < 45% (approx 50:50 split) - More likely to have anthracycline (AC) younger, better PS, EF 45-49% - AC assoc with much better PFS & OS Only drop the AC when you really have to! #ASH23 #lymsm

Post attachmentPost attachmentPost attachmentPost attachment
Dr. Patrick Hwu avatar
⟳ Narendranath Epperla, MD, MS, FACP retweeted
Dr. Patrick Hwu@PatrickHwuMD·2 Dec 2023

#ScienceSaturday Can dietary nutrients help the immune system kill #cancer cells? In this study, researchers screened 255 circulating nutrients for the ability to enhance T cell activity and found that the long-chain fatty acid TVA (Trans-vaccenic acid) could enhance the activity of CD8-positive “killer” T cells against cancer. This impressive work has significant implications for cancer #immunotherapy and beyond. Here’s a link to the full article. nature.com/articles/s41586-0…

Post attachment